Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Aiforia, Webcast, Q2'25

By Inderes8/28/2025, 10:00 AM
Aiforia Technologies

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jukka Tapaninen
00:11 - 11:17

Good afternoon. My name is Jukka Tapaninen, and I am the CEO of Aiforia. And welcome everybody to the first half earnings announcement today. So I'm going to give some highlights of what happened in the first six months. And Veli-Matti, our CFO, will go through the numbers. And then I will highlight a little bit of our strategy going forward. But let's get started. The first half of the year. So, it was, in many ways, I think, really, really good. So, we have some new closings on the customer side. And I will cover these in a later part of the presentation. So our order book grew by 58% compared to last year's situation. So, on the revenue side, we were flat. But there are some good reasons why that happened. But all in all, on the sales side, we achieved good success and we were progressing as planned in acquiring those initial clinical customers, allowing us to use them as a reference. And we can scale with those customers as well as use them as a showcase for others. Significant amounts of those clinical agreements were completed. But what was, I think, even more important than winning those customers. So was the regulation part, because as we are dealing mainly now on the clinical side, of course we have research customers. But the focus, where we think from a commercial perspective the business is growing, is the clinical sector. And there you need a lot of different kinds of certifications related to security. And then we have this medical device category where we have our solutions. So we obtained the IVDR certification. That's the new regulation for Europe. So it used to be CE-IVD and it is still CE-IVD but now falls under the IVDR regulation. So. So we made significant progress on that side, which is crucial because we have been able to build the largest portfolio of CE-IVD solutions in this marketplace. And that gives us a good opportunity to move forward. And of course, we are not alone. So this is, this is kind of an interesting marketplace. So you have scanner vendors, you have laboratory information system vendors, image management vendors, and AI vendors. And then you have a kind of reselling partner. So we've been moving forward on all of these fronts by strengthening partnerships and trying to find new ways to reach the market with those companies. Just wanted to show this because if we look at the history, and not going back to the ten years when the company was set up, but building the core of the technology and getting the research customers, but in 2020. We decided to focus on the clinical side due to commercial reasons and multiple other factors. So there's a huge need for additional resources and quality improvements. And of course, all of those things that AI can provide, offering capabilities beyond what the human eye can achieve. But anyhow, in 2020, we decided to enter the clinical market. In 2021, we won the first major deal with Mayo Clinic, the number one hospital in the world. So that's the best reference you can get in this industry. In 2022, we introduced the first five CE-IVD solutions and have since been gradually increasing the number of clinical closings each year. So in 2023, there were three. Last year it was five closings. And the first half of the year. This year we closed five. So we are on a good track to achieve our targets on that side, but just to name a few. So, the NHS was, of course, a nice deal. Then the Memorial Hospitals Group in Turkey. So that's important as well. So they took five AI models from our portfolio. So, it's the biggest private hospital in Turkey. So that's a really important one. And then we have a lot of deals from Italy. So that was kind of a, yeah, there was kind of some acceleration coming from the European Union because there's this Covid recovery fund. So far, there are 15 hospital regions in Italy. So we have closed actually seven today and a couple of really meaningful ones. So Veneto region 5.5 million people. So on that particular opportunity. So now we are going to go to the next phase because solutions are implemented. And now, they continue to use it. So that's probably the first real case as this business should be kind of evolving going forward. But then the Lombardy region that we closed earlier this year is really significant. So if Veneto were the size of Finland, Lombardy would be the size of Sweden. So it's about 10 million people in that region, 31 hospitals. And we could use Veneto as a reference for Lombardy. So actually, the customer said, quote, that okay, we want to have exactly the same system as Veneto has because they wanted to get the best practice and guarantee that it has been implemented successfully by multiple others. And I think Fimlab in Finland is a really important deal for us as well. There were multiple lots for which they chose Aiforia. So they chose solutions for nine different areas. And Aiforia is part of all of those. And in a couple of areas, there are competitors offering their solutions. As far as I know, Aiforia is also the only company that has received actual orders from that public tender. So obviously, we try to serve our key customer in Finland as best as we can. So, and make the customer happy in that way. But my point is that there are multiple good closings. And the Paris region, for example. So that's the biggest hospital group in Europe. So 38 hospitals. Now, we have delivered one AI model to a couple of hospitals. But there is a huge upsell opportunity. And even more important than that is that now we are in France. So we have delivered something, and we are considered as a French company. The French government is now supporting the adaptation of AI in hospitals. So they are giving grants so that hospitals can make the initial investment in this area. So, and we are on all of those kinds of public sector buying portals, and all that kind of bureaucracy really related to the French market is sorted out. We also kind of set up a legal entity so that we see that the market is the next big thing, uh, after Italy. But, all in all, I think Europe is doing quite strong on this AI side. What else? Uh, so of course, we are kind of a technology company in a new market, and we keep investing so that we stay ahead in technology. Currently, our offering is the widest and deepest in that sense, so we can really provide the information that pathologists need for their decision-making and provide efficiencies and accuracy in doing that and a readiness to go to the next level as well. We've been investing in integration with multiple image management companies and LIS vendors so that it's easier to scale, but that's something that you need to do. And it doesn't show as a kind of it's not really visible, but you need to ensure your solution works with all the leading vendors in the market. And from this slide, I think the biggest point is the last bullet point. So, it's the Aiforia® Create. So that's our development platform. And we've been updating that technology. So we've been heavily invested in foundation models. And we are using transformers. So we are connecting with third-party foundation models and getting ahead in that technology. So it means basically that we have the current version. The older version. So, which is a CNN (Convolutional Neural Networks)-based kind of AI engine. And now we are bringing on-site this foundation model technology. And I think what is meaningful here is: what does it actually bring? What are the current buzzwords and trends happening in the industry? But the important thing is that we can develop models faster, cheaper, and with better quality. I think these are the three key benefits that come from foundation models: faster, cheaper, and higher quality model development. And obviously, we are kind of keeping a tight look on what's happening in the market from a technology perspective so that we can leverage all the latest innovations in the market. This is what I already mentioned. So, it's really, really a big thing. So because, on May 22nd, Europe changed the regulation. Before that, it was CE-IVD. And then on May 22nd. So they introduced this new enhanced regulation. IVDR. And we started to build our processes, document them, and conduct audits. It took some time because there were no notified bodies in the beginning. So on and so forth. But all in all, the good thing is that we have done this groundwork for this regulation. We have been accepted. So, we have that in place under the new regulations, allowing us to bring AI models. So we don't need to do all the initial steps again. So, but now we can focus on bringing new AI models to the market. And this is the main thing if you think about it. So as I said, medical device and CE-IVD marking are essential. So, if you want to sell in a clinical market, there are only a few companies who can actually do that. You can always have those discussions so that yes, somebody can build an algorithm. However, that's not the solution that you can deliver. No regulation, no kind of maintenance cycles, user experiences, all of those things that a software company needs to have in place. So we have that, and I think we are ready to scale on that side. But I will now hand over to continue with the numbers. And I will come back with the strategy update at the end. Thanks Jukka.

Veli-Matti Parkkonen
11:18 - 15:18

And, uh, good afternoon from my side as well. In the following, I would go through some of the key financials from our first half 2025 report. So as mentioned, our revenue growth was 2%, reaching 1.4 million. And most of that came from Europe. Finland represented 14%, and North America 25%. The order book growth was 58% to 5.1 million, and we actually invested 3.7 million for total product development. Development was the main part of that 3.6 million. That's about 1 million more than last year. And as you mentioned, there was successful progress in our product development, in AI models and also this new AI engine, which is great news for me as well because, I mean I have to check out the costs. We had, on average, 69 employees during the quarter. That's a pretty significant decrease from last year. But on the other side, we have welcomed new colleagues already this month who have started, and we're going to wait for a couple more to start within a month or two. We had €11.9 million cash at the end of the period. The revenue growth was flat. So pretty much the same levels as, uh, the year before. But if you look at the figures, you could see that the clinical business growth was approximately 60%. And if you add on that, the delivery you mentioned would have happened, let's say, in the first half. So, so the growth would have been something. Overall growth would have been approximately 35%. And the clinical growth was over 100%. The order book growth has been 58%, and that came from the clinical business. So the growth was 2 million, or 90% from the year before. And in terms of costs, we are pretty tight on managing them. Although the employee costs went down to 3.7 million, the other operating costs went up to 4 million. And that's due to the fact that we invested significantly in computing power. The cloud costs increased. And also we purchased quite a bit of samples to enable the model creation, which also increased the other operating costs compared to last year. But obviously, I mean, we are in a growth phase in the sense that we still maintain and have a strong mandate from our investors. A couple of months back, we decided that we should keep up the progress on the product development that the market requires. But this is pretty much from my side. And thank you, Jukka.

Jukka Tapaninen
15:19 - 27:59

Yeah. I just wanted to point out on the numbers. As Veli-Matti said, on the clinical side, we grew 60%. So overall growth was 2%. But the devil here is in the details as well. So that we decided to go into the clinical market, we decided to build a portfolio for that market and also captured the first big customers. And on that roadmap. So we've been moving forward very, very well. So. And because if we look at the profitability on a research side and a clinical side, obviously we see that the profit will come from the clinical side. And now we have kind of taken the first steps on that side of the business. And it seems to be growing quite nicely. But this strategy. So, I've been showing this slide a few times, but it's still very valid. So there's an active problem recognition. So, our customers, they know that they need something. So they're actively looking for solutions. That's why the large flagship hospitals are really important. And the reference value they gave is really, really important in this phase so that someone can show what the best practice is, how it will be delivered, what type of components, and what type of solutions you need to build a kind of working model. And demand is going up. So the cancer rates are going up. Aging population, all of those same basic factors are present, and also the capacity. In different continents and countries, there is no situation where there is an overcapacity of pathologists. So there would be an overcapacity of pathologists. So there is a need and that need is growing. So our kind of play or place in this workflow. So we are talking about the physical samples, where if there is a prediction that you might have cancer, it leads to a tissue sample, which will be prepared and scanned. And then it comes to a software piece which is responsible for uploading those images, sharing them with pathologists, and storing them. And what currently drives the market forward is AI. And that's the area where we are. So we are the ones who understand what's on those samples. So we can extract the information from those huge files, even though they are physically small. But we are talking about images that are two gigabytes in size. And then you are looking for really, really tiny details. But what Aiforia can do here is remarkable. So we do it much better than any of our competition, as we not only provide heat maps, but we also go deeper. So we do a quantitative analysis. We populate the report. We actually give the information that the pathologist needs for their decision making. And that is in hot demand at the moment. So, that drives the demand for the image management vendors, the software vendors. And that drives the demand for the scanner vendors as well. Of course, if you turn it around, scanner penetration is an important piece as well, so that they have the devices to actually obtain the digital images and then use an AI. So all in all, they are connected to each other. So what we have, we have the technology leadership. So we use the foundation models, Transformers. We use CNN, which is the latest technology as well, and it is already working and deployed. So we are recognized as a leader on this side. So we have a scalable business model. Now we have a couple of customers moving from the first phase to the phase where they are actually using the software and paying for the usage. So, and that's a profitable part for us because in the first phase, you need to invest in selling. You need to invest in delivering the solution. But once it's there and the customer is ready, you can add more AI models and scale up the usage, which is good for the software company's interoperability. As I said. So we are connecting with multiple systems. And we have interoperability agreements and testing done with multiple scanners and multiple image management systems. And the last point, this is something substantial. So I would like everyone to focus on this as well. So it's a certified quality to be able to operate in the US hosting patient data, you need to have HIPAA compliance. So you need to have multiple different kinds of security regulations and certifications in place. You need to have some patents. And now you need to have the IVDR regulated products and CE-IVD products under that, meaning that it's a heavy investment. So, this is a barrier to entry for this industry for sure. Because anyone who wants to enter this industry, it takes time to obtain all of those certifications. Then we have it, and we can now start selling in volume on that side. Just a visualization of our differences. But we've been looking at the main areas where we want to partner with. So, I have to say we have a pretty good offering at the moment. And that's the broadest offering in the market at the moment. So, and then of course we have a pipeline of new, upcoming products as well. And this is an interesting picture because four years ago when we did the IPO, we said, okay, we didn't have any CE-IVD in those days. And we said, okay, our strategy is to build a portfolio of solutions that allows users to cover 80% of the workflow. So we decided that we bring all the relevant solutions with high quality, and we aim for 80% coverage by the end of a decade. So currently, we have a 60% coverage. So we cover all the major disease areas in pathology. So this is something that, as a company, we are really, really proud of, and of course, we are now working on increasing the number closer to 80. But we are well on track to meet that target. And then coming back to the growth rate of 2% versus 60%. So, I picked the 60% because we've been focusing on getting these flagship customers in place and growing the clinical business, as this gives us the opportunity to scale up significantly. In 2021, we secured the Mayo Clinic, and then we developed those solutions. So there were three closings in Q1 2023. This, by the way, is not all the closings, but these are the ones that we've been focusing on because we also set a target to have 15 types of customers where there's potential revenue over half a million. So, annual recurring revenue is over half a million. So that it doesn't happen in the first year. So, there's an opportunity to build up those customer relations at that level. And last year, there were five closings. A really interesting one I mentioned is Castilla y León. Interesting one. And that's a fantastic deal. So it's a big region in Spain. First good referenceable customers together with the Swedish image management vendor sector. So it's a fantastic deal. The challenge there was that they wanted to have a local implementation. So now we are delivering that. So it will happen in Q3. But also, that was impacting a little bit on the revenue that we could book in the first half of the year, so we actually could have done a little bit better on a Rev Rex. But the main point is that it will now be delivered, and we provide a fantastic solution to the end customer. But those are the closings from last year and this year. So five meaningful closings in the first half of the year. And you can show that. See that, okay. France is really picking up. So, a couple of hospitals from the Assistance Publique-Hôpitaux De Paris. So we want the Nantes region. So a really good reference. And they have already announced that they are using Aiforia. And we got the deal. So that's why it's on a list. But really, it was a series of nice closings. And Lombardia is, of course, commercially also a significant player. So, moving forward, and so far, every tender that we've participated in, we have been winning. In some cases, they've chosen one or two other vendors for the same tender, but we haven't lost any, so that's good to keep in mind as well. And going forward, I know there are questions coming, such as how do we accelerate. So where, or rather when, do we actually see the revenue growth happening? So, we had a big strategy exercise a couple of months ago. And the outcome is that, okay, we see the opportunity in Europe. The scanner penetration is approximately 30% in Europe. So, it sounds low but significant. But okay. So it's actually much better than elsewhere in the world. And then we see these public fundings speeding up the adoption. And that's why, as a European company, it's natural that we want to capture that opportunity and accelerate the business in Europe. We will grow the clinical offering. So there will be more CE-IVD marked solutions coming up. And we look at other kinds of opportunities, considering how we can improve the user experience close to our core and domain. So, but we've been obviously planning all of these different areas. So, how much revenue and what type of growth will come from those areas? But this is at a high level, considering both short-term and long-term aspects. This is obviously truly a global business. We have a good presence in the US, so we want to capitalize on that and start investing again in the US. Uh, going forward. Then we have some interesting ones. So I mentioned that when you talk about AI currently, what we offer is efficiency. You can do much more with the same resources. You can do it with better quality. You avoid mistakes. But the other thing is that now the prognostic models are advancing rapidly and showing significant potential in improving outcomes. What we've built with the Mayo Clinic allows for the prediction of patient outcomes. Combining the Bayesian data, integrating it with AI-driven data. This is something that builds up the value of AI. First, the efficiency aspect. But now the additional value is coming from things that you can't really do with the human eye. So then we have also been talking with a couple of pharmaceutical customers. And by the way, I didn't mention that Orion was a nice win from Finland on that side where we sell an Aiforia study solution. So that's in good shape. But in the context of pharma, we're referring to companion diagnostics. And we've been proactively approached by a couple of very large pharma companies who are considering that when they are developing a medicine, they need to integrate AI so that AI can drive certain results based on that outcome. So, you can then provide certain treatments or specific medicines to the patients or implement companion diagnostic approaches, but those are long-term initiatives. So that's why I put it in 2030, even though some of those discussions have already started. But this is a really interesting marketplace. And there's a good opportunity to make it a really nice business. That's it from my side. And now there's room for some questions. I know that Antti is already ready.

Unknown 1
28:01 - 28:26

Okay, let's start from the top line and then go a bit further into the financials. But first of all, on the revenue, of course, it's been on a relatively flat level for the last two years. And we've seen that the preclinical revenue has decreased, while the clinical side has been taking over. Do you think this will be a recurring trend that the pre-clinical will be going sort of down, or do you think there's room to bring that up again?

Jukka Tapaninen
28:26 - 29:03

Yes. In relative terms, it will definitely decrease. But in absolute terms, I think it will stay more or less at the same level, but our focus is really on building up the clinical business. And I have to say one thing: we have an offering, Aiforia® Create, which is a fantastic development tool mostly used in research. So it's something that makes us really strong in a clinical sales situation. So, because we can combine the offering, the focus is clearly on the clinical side.

Unknown 1
29:03 - 29:13

Right. And when you say the pre-clinical, you expect it to be roughly on the same level in absolute terms. Is there a sort of cyclical element that drives that up and down between?

Veli-Matti Parkkonen
29:13 - 30:20

Not really. I mean, I think it's quite stable going forward. So, so it's kind of easy to predict because it's a type of license-based or SaaS play in that sense. So you pocket the license fees upfront and then you recognize them throughout the license period. So it's pretty stable. But I say that. So previously, when we tried to define business anywhere, we faced challenges. So, obviously, let's say, in the US, it was easier to get those research pre-clinical type of clients. And then you were capable of attracting some of those who did some projects, going forward. But now, since we are more concentrating on the clinical side, that has kind of dropped out from the baseline revenue base. So, so it's stable and going forward. I, as you mentioned, the research part includes the pharma companies. I think we have a great chance to take that business as well going forward.

Jukka Tapaninen
30:20 - 31:11

But everything we have done so far has some meaning. So if we think about ten years ago when we started. So we started to build a platform that enables the creation of these AI models. We brought out the first kind of version of Create in 2017. So we started to get research customers because it's a fantastic tool for them. So the outcome is that we got 5,000 users from all the major universities and the research groups. We got a lot of scientific, uh, documents out of that. So there are proof points that the technology works. And then we go to 2020. So when we started using that technology to build the offering for the clinical side, we didn't want to give away the research business, but we acknowledge it will go there. So, but it's not something that you can scale up significantly. So, but the clinical side. Not really.

Unknown 1
31:13 - 31:22

And then on the clinical side, were there any projects or customers where there were some timing effects, some deals, and revenue getting booked to, let's say, H2 for example, instead of H1?

Jukka Tapaninen
31:22 - 32:00

Well, I think we are quite positive on an annual level. I mentioned the Spanish deal where the customer required delivery on-premise due to the tender rules clearly stating the need for it. And that was the first on-premise delivery for us because we are cloud-native and everything is in the cloud, but in this case. So we, of course, wanted to do what the customer asked, and it took a couple of months longer. So it should now be kind of delivered in Q3. But that was roughly about a half a million deal, and a big part of that money was significant. So we could have actually recognized it in the first half. Yeah.

Unknown 1
32:00 - 32:22

So it should now be delivered in Q3. Thanks. That's helpful. And then on the order book, um, of course, it has risen from the last year's levels, but then compared to the year-end last year, it has actually come down slightly. It was roughly at 5.2 then. Now it's 5.1. Uh, can you explain this dynamic a little bit? Is there some sort of contract rotation being booked into revenue and not rebooked in the order book? What's the dynamic there?

Veli-Matti Parkkonen
32:22 - 32:59

That's pretty much as you explained. So the big drop, I would say, of a couple of hundred thousand comes from the order book on the research side. So the clinical side has been flat or growing slightly. Not as much as we wished, but there were some negotiations going on, which hopefully would close up this half. So it's a bit tricky to forecast how they will be seen, but the pipeline is quite nice.

Jukka Tapaninen
32:59 - 33:25

Yeah. Yeah. I am aware that there's a slight disconnect, where you saw the 2% number and previously asked if I'm happy with the results from the first half. Absolutely. I'm happy. So, if you think about the clinical growth at 60%, then a couple of deals moving to the second half. So we could have had quite nice numbers. And I think the clinical side is absolutely on target from that perspective.

Unknown 1
33:27 - 33:41

And then on the cost, and overall, where are you investing as a company? So your employee count was coming down a little bit in the spring. And now you've recruited back again. Have you made some shifts in priorities, and if so, where have you?

Veli-Matti Parkkonen
33:41 - 33:41

Yes.

Unknown 1
33:41 - 33:42

That's correct.

Veli-Matti Parkkonen
33:42 - 34:24

That's correct. And obviously, I mean there's going to be a rotation going forward. So we'll be increasing the number of sales and support type personnel. But on the other hand, we maintain the high level of investment in product development. So, that's kind of like the change. So there has been a rotation in the personnel. But obviously, you want to guarantee that you get the best possible people back. So whenever you recruit, it's not happening like that. It's not like a McDonald's type of recruitment going forward.

Jukka Tapaninen
34:24 - 34:25

Yeah.

Veli-Matti Parkkonen
34:25 - 34:25

Sorry.

Jukka Tapaninen
34:26 - 34:45

But also, as we are using the latest technologies. So then, in software development, you can utilize the latest technologies. So if you use all of those tools, you don't necessarily need so many more resources, and you can allocate those a little bit differently now because the AI is helping to take out certain things.

Unknown 1
34:46 - 35:09

Yes. That's helpful. And then also on the cost side, you mentioned that you've been buying some samples for R&D purposes. And that was one cost item in H1. Um, how do you see that area going forward? Of course, you mentioned you are already targeting around 60% coverage in the pathology workflow by the end of this year. How do you see that area moving forward? Do you still have needs?

Veli-Matti Parkkonen
35:09 - 35:47

Yeah. There will definitely be a need. So going forward, you need to have a certain level of investments in those samples. And we are a data company. So obviously, we have to have a certain type of approach to acquiring data, whether it's samples or some other type of resources. But, data is kind of like our core. It's like the template's page deal. One of the arguments for why they did that was the data acquisition. So, um, definitely we're going to, but we have to justify what's the right level for us compared to the top line growth.

Unknown 1
35:48 - 36:11

That's good. And then on the US market, of course, regarding your strategy now, you mentioned that the focus would be more on Europe in the coming years and then on the US more in 2030 and onwards. Um, of course, you've been thinking of the FDA application as one element, but should I not read into this too much and say that it has moved forward several years, or are you still thinking actively about the FDA?

Jukka Tapaninen
36:12 - 36:30

Yes, we have been dealing with the FDA. So we submitted the first application. So, and we received the feedback. So we have a clear idea of how we are going to do it. So whether it's happening this year or next year. So I'm not going to share that information. It could take some time. So, but it's definitely in our strategy to do it.

Unknown 1
36:32 - 36:33

Good. It's like a templated page deal. That's all from me.

Unknown 2
36:36 - 37:06

It's like the template's page deal. It's like the temple's page deal. Audience here in Helsinki. And now we will take a couple of questions from our online audience. So there are a couple of questions regarding the order book. And it was, roughly the same level as it was at the end of last year. So is it a fair assumption to say that? The latter half of the year will be stronger in regards to order book development?

Veli-Matti Parkkonen
37:07 - 37:15

I can't give any forecast for that. But obviously, I mean that's the target and aim for us, that it's going to grow.

Jukka Tapaninen
37:16 - 37:29

Yes. What I can say is that, okay, we have a healthy pipeline of business. So it seems that the market is really opening up. Whether we capture all of those opportunities remains to be seen. So we'll see that. So, but currently, it looks really, really promising.

Unknown 2
37:29 - 37:45

Thank you. Uh, then uh, further with the order book. So, uh, revenue grew by 2%. So why didn't the order book turn into revenue during the first half?

Jukka Tapaninen
37:45 - 39:02

Yeah, there are two things. So, and you may comment more, but from my perspective, two big things are the Lombardia region. So we closed that in January. So, and the delivery hasn't started yet. So as we are kind of moving forward with the. Uh, kind of uh, and uh, so we cannot book the revenue until we start delivering something. And we expect that the deliveries for that particular deal will start in the second half of the year. And I already mentioned a couple of times about the Castile-Leon case in Spain. So that's the same thing. So that's happening right now as we speak. But okay, that will be kind of revenue for the second half of the year and what comes to recognize. So I think we pretty much know all the deals that we are going to recognize, because those have already been sold and are now in the delivery phase. So there are a couple of bigger customers. So, that's okay, because we need to deliver and the customer accepts the solution. So, and then we can book it as revenue and continue moving forward. So then it's a pipeline and all of those open cases because it's not likely that we close something now and deliver before the end of the year. So, and recognizes revenue. But we have a good, clear visibility for the second half.

Unknown 2
39:04 - 39:19

Thank you. And still further regarding the order book. So how do you recognize the orders in the order book? So, is that the total value of the contracts throughout the whole contract length?

Veli-Matti Parkkonen
39:20 - 39:23

That's correct. That's the right interpretation.

Unknown 2
39:24 - 39:33

Thank you. That was all today from our online audience. And any further questions from the audience here in Helsinki? Okay.

Veli-Matti Parkkonen
39:33 - 39:59

Thank you. I would also like to comment on the last question, obviously the person is interested. What's the duration of our order book? So, it's a bit less than two years on average. So, that might clarify how we could approximately recognize those orders.

Jukka Tapaninen
40:00 - 41:13

And my closing words. There are three points. It's kind of fashionable to outline three points. But first of all, keep in mind that we started the journey on the clinical side in 2020. So, we have been able to build the biggest and best portfolio in that market. So with the regulatory approvals. So that's the first thing. The second thing is that, okay, so we have actually won real customers, really kind of leading hospitals from the US, from Europe, from the main markets. We have started delivering to some customers, and some deliveries are already ongoing, showing strong progress. So, onto the next phase; the third point is, okay. So now it's time to kind of scale up. And that happens with different partnerships and strengthens our own sales efforts, but also involves finding new ways to the market through partnerships and channels as well. So, but I think we are in a good position. And the last point: keep in mind the 60% growth in clinical, but don't mix it up with the 2% overall growth because that's related to the preclinical sector, which is not growing as fast, but it is an area we are focusing on. So that's growing really nicely.

Unknown 2
41:17 - 41:18

Thank you, thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…